Sort
15,273 grants matching “antimicrobial resistance”
WE ORIGINALLY DEVELOPED SELF-DESTRUCTING ATTENUATED ADJUVANT SALMONELLA (SDAAS) STRAINS TO DELIVER PATHOGEN-ASSOCIATED MOLECULAR PATTERNS (PAMPS) AND DAMAGE-ASSOCIATED MOLECULAR PATTERNS (DAMPS) TO PATTERN RECOGNITION RECEPTORS (PRRS) TO AUGMENT ABILITY OF SUBUNIT AND LIVE VACCINES TO INDUCE PROTECTIVE IMMUNITY. THESE LIVE STRAINS EFFICIENTLY COLONIZE MUCOSAL SURFACES AND INVADE LYMPHOID TISSUES TO ACTIVATE INNATE IMMUNITY EFFECTORS. WE THEN DEMONSTRATED THAT SDAAS STRAINS WERE SAFE AND EFFICACIOUS FOR IN OVO ADMINISTRATION TO 18-DAY-OLD CHICKEN EMBRYOS TO ACHIEVE NORMAL HATCHABILITY. CHICKS HATCHED FROM THESE IN OVO INOCULATED EMBRYOS DISPLAY INCREASED PROTECTION AGAIN COLONIZATION BY S. TYPHIMURIUM. WE THEREFORE PROPOSE TO FURTHER OPTIMIZE SDAAS STRAINS FOR DELIVERY BY COMMERCIAL MEANS USED IN HATCHERIES AND EVALUATE THEIR ABILITY AFTER IN OVO ADMINISTRATION TO REDUCE NATURAL MEANS OF COLONIZATION BY SALMONELLA, CAMPYLOBACTER JEJUNI, CLOSTRIDIUM PERFRINGENS AND APEC STRAINS. WE WILL ALSO INVESTIGATE ALREADY CONSTRUCTED PROTECTIVE IMMUNITY ENHANCED SALMONELLA VACCINE (PIESV) CONSTRUCTS (AND ONE TO BE MADE AGAINST APEC STRAINS) TO BE CO-ADMINISTERED WITH SDAAS STRAINS BY IN OVO INOCULATION OR BY COURSE SPRAY AT DAY-OF-HATCH TO AUGMENT LEVELS OF PROTECTIVE IMMUNITY TO THESE PATHOGENS. OUR ULTIMATE GOAL IS TO ENSURE SAFE EFFICACIOUS IN OVO INOCULATION TO STIMULATE PRODUCTION OF SUSTAINED INNATE IMMUNITY AND CONFER IMPROVED PROTECTIVE IMMUNITY AGAINST SALMONELLA, C. JEJUNI, C. PERFRINGENS AND APEC INFECTIONS AND DISEASE. SUCCESS WILL LEAD TO HEALTHIER CHICKENS, WITH IMPROVED FEED CONVERSION AND INCREASED WEIGHT GAIN, REDUCED USE OF ANTIMICROBIAL DRUGS MINIMIZING SELECTIVE PRESSURE FOR EXPANSION IN DRUG-RESISTANT BACTERIA AND REDUCE PASSAGE OF ENTERIC PATHOGENS THROUGH THE FOOD CHAIN TO HUMANS
$650,000University Of Florida · · FY2025 · National Institute of Food and Agriculture
Collaborative Research: URoL:ASC: Using the Rules of Antibiotic Resistance Development to Inform Wastewater Mitigation Strategies
$650,000Liqing Zhang · Virginia Polytechnic Institute And State University · · FY2023 · BIO
Rapid fungal identification and antifungal susceptibility testing through quantitative, multiplexed RNA detection
$649,802Roby Paul Bhattacharyya · Broad Institute, Inc. · R01 · FY2023 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte
$649,768Jon Clardy · University Of Wisconsin-Madison · U19 · FY2015 · AI
Using an in vivo multi-lifetime model to test mechanisms of aging
$649,679David Masopust · University Of Minnesota · R01 · FY2024 · AG
Roles of novel cationic lipids in bacterial pathogenesis
$649,409Kelli Lea Palmer · University Of Texas Dallas · R01 · FY2025 · AI
Roles of novel cationic lipids in bacterial pathogenesis
$649,409Kelli Lea Palmer · University Of Texas Dallas · R01 · FY2024 · AI
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease
$649,379M. Javad Aman · Abvacc, Inc. · R01 · FY2024 · AI
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
$648,979Lisa E Manhart · University Of Washington · R01 · FY2021 · AI
Dynamics of the cellular and molecular architecture of human pulmonary TB granulomas
$648,711Robert L Modlin · University Of California Los Angeles · R01 · FY2024 · AI
H. influenzae: Role of Sialic Acid in Virulence
$648,648Michael A. Apicella · University Of Iowa · R56 · FY2009 · AI
Development and evaluation of a second-generation fungerp for systemic and cutaneous C. auris infection
$648,567Mahmoud A Ghannoum · Case Western Reserve University · R01 · FY2024 · AI
Development and evaluation of a second-generation fungerp for systemic and cutaneous C. auris infection
$648,567Mahmoud A Ghannoum · Case Western Reserve University · R01 · FY2025 · AI
Trial of Zinc Supplements for Young Infants with Clinical Severe Infection in Tanzania
$648,541Christopher Sudfeld · Harvard School Of Public Health · R01 · FY2023 · AI
Proteasome inhibitors against mucosal protozoan pathogens
$648,435Lars Eckmann · University Of California, San Diego · R01 · FY2024 · AI
Proteasome inhibitors against mucosal protozoan pathogens
$648,435Lars Eckmann · University Of California, San Diego · R01 · FY2022 · AI
Proteasome inhibitors against mucosal protozoan pathogens
$648,435Lars Eckmann · University Of California, San Diego · R01 · FY2023 · AI
Proteasome inhibitors against mucosal protozoan pathogens
$648,435Lars Eckmann · University Of California, San Diego · R01 · FY2021 · AI
Proteasome inhibitors against mucosal protozoan pathogens
$648,435Lars Eckmann · University Of California, San Diego · R01 · FY2025 · AI
Defining the targets of broad intervention antimalarial agents
$648,140Elizabeth A Winzeler · University Of California, San Diego · R01 · FY2013 · AI
Lung-Protective Mechanisms of Metformin in TB
$647,877Hardy Kornfeld · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · HL
Dynamics of the cellular and molecular architecture of human pulmonary TB granulomas
$647,775Robert L Modlin · University Of California Los Angeles · R01 · FY2023 · AI
Deciphering fundamental biological processes involving protein-nucleic acid interactions at the molecular level
$647,751Maria Schumacher · Duke University · R35 · FY2025 · GM
Deciphering fundamental biological processes involving protein-nucleic acid interactions at the molecular level
$647,751Maria Schumacher · Duke University · R35 · FY2024 · GM
Taste of medicines for children: genetic variation and medical adherence
$647,633Julie A Mennella · Monell Chemical Senses Center · R01 · FY2020 · DC